Bliss GVS Pharma (506197) Q4 12/13 earnings summary

Executive summary

• FY13 total revenue rose 30.34% YoY to ₹36,871.60 lakh; PBT increased 31.51% to ₹10,483.23 lakh, while PAT rose 7.29% to ₹5,668.20 lakh.

• Export-led operations, niche suppository and pessary products, and branded generics supported growth; nearly 95% of revenue was attributed to exports.

Financial highlights

• Standalone revenue from operations was ₹35,368.32 lakh versus ₹26,707.06 lakh YoY; other income was ₹1,503.28 lakh versus ₹1,585.85 lakh.

• Standalone PBT was ₹10,483.23 lakh versus ₹7,971.25 lakh; PAT was ₹5,668.20 lakh versus ₹5,282.90 lakh.

• Consolidated revenue was ₹41,069.52 lakh versus ₹28,282.19 lakh; PBT was ₹10,948.24 lakh and PAT after minority interest was ₹5,772.01 lakh.

• Standalone net sales reached ₹35,368.32 lakh versus ₹26,707.06 lakh; reported FX gains of ₹863.65 lakh contributed to profit.

Outlook and guidance

• Completed a new R&D laboratory in FY13 to develop formulations for suppositories, pessaries, and other dosage forms, supporting entry into European markets.

• Plans focused on new markets, including Europe and the USA, and expanding anti-malarial, anti-fungal, and antibiotic products; no quantified earnings guidance was stated.

• Future plans included local manufacturing units and joint ventures, with a Singapore subsidiary overseeing export business.